Literature DB >> 17182694

Cytosolic prion protein toxicity is independent of cellular prion protein expression and prion propagation.

Eric M Norstrom1, Mark F Ciaccio, Benjamin Rassbach, Robert Wollmann, James A Mastrianni.   

Abstract

Prion diseases are transmissible neurodegenerative diseases caused by a conformational isoform of the prion protein (PrP), a host-encoded cell surface sialoglycoprotein. Recent evidence suggests a cytosolic fraction of PrP (cyPrP) functions either as an initiating factor or toxic element of prion disease. When expressed in cultured cells, cyPrP acquires properties of the infectious conformation of PrP (PrP(Sc)), including insolubility, protease resistance, aggregation, and toxicity. Transgenic mice (2D1 and 1D4 lines) that coexpress cyPrP and PrP(C) exhibit focal cerebellar atrophy, scratching behavior, and gait abnormalities suggestive of prion disease, although they lack protease-resistant PrP. To determine if the coexpression of PrP(C) is necessary or inhibitory to the phenotype of these mice, we crossed Tg1D4(Prnp(+/+)) mice with PrP-ablated mice (TgPrnp(o/o)) to generate Tg1D4(Prnp(o/o)) mice and followed the development of disease and pathological phenotype. We found no difference in the onset of symptoms or the clinical or pathological phenotype of disease between Tg1D4(Prnp(+/+)) and Tg1D4(Prnp(o/o)) mice, suggesting that cyPrP and PrP(C) function independently in the disease state. Additionally, Tg1D4(Prnp(o/o)) mice were resistant to challenge with mouse-adapted scrapie (RML), suggesting cyPrP is inaccessible to PrP(Sc). We conclude that disease phenotype and cellular toxicity associated with the expression of cyPrP are independent of PrP(C) and the generation of typical prion disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17182694      PMCID: PMC1866012          DOI: 10.1128/JVI.02157-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Wild-type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation.

Authors:  J Ma; S Lindquist
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-11       Impact factor: 11.205

2.  Proteasomes and ubiquitin are involved in the turnover of the wild-type prion protein.

Authors:  Y Yedidia; L Horonchik; S Tzaban; A Yanai; A Taraboulos
Journal:  EMBO J       Date:  2001-10-01       Impact factor: 11.598

3.  Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol.

Authors:  Jiyan Ma; Susan Lindquist
Journal:  Science       Date:  2002-10-17       Impact factor: 47.728

4.  Cytosolic prion protein in neurons.

Authors:  Alexander Mironov; Diane Latawiec; Holger Wille; Essia Bouzamondo-Bernstein; Giuseppe Legname; R Anthony Williamson; Dennis Burton; Stephen J DeArmond; Stanley B Prusiner; Peter J Peters
Journal:  J Neurosci       Date:  2003-08-06       Impact factor: 6.167

5.  De novo generation of a PrPSc-like conformation in living cells.

Authors:  J Ma; S Lindquist
Journal:  Nat Cell Biol       Date:  1999-10       Impact factor: 28.824

6.  Anchorless prion protein results in infectious amyloid disease without clinical scrapie.

Authors:  Bruce Chesebro; Matthew Trifilo; Richard Race; Kimberly Meade-White; Chao Teng; Rachel LaCasse; Lynne Raymond; Cynthia Favara; Gerald Baron; Suzette Priola; Byron Caughey; Eliezer Masliah; Michael Oldstone
Journal:  Science       Date:  2005-06-03       Impact factor: 47.728

7.  Inherited prion disease caused by the V210I mutation: transmission to transgenic mice.

Authors:  J A Mastrianni; S Capellari; G C Telling; D Han; P Bosque; S B Prusiner; S J DeArmond
Journal:  Neurology       Date:  2001-12-26       Impact factor: 9.910

8.  Doppel-induced cerebellar degeneration in transgenic mice.

Authors:  R C Moore; P Mastrangelo; E Bouzamondo; C Heinrich; G Legname; S B Prusiner; L Hood; D Westaway; S J DeArmond; P Tremblay
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

9.  Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol.

Authors:  Jiyan Ma; Robert Wollmann; Susan Lindquist
Journal:  Science       Date:  2002-10-17       Impact factor: 47.728

10.  In vitro generation of infectious scrapie prions.

Authors:  Joaquín Castilla; Paula Saá; Claudio Hetz; Claudio Soto
Journal:  Cell       Date:  2005-04-22       Impact factor: 41.582

View more
  6 in total

1.  Alternative translation initiation generates cytoplasmic sheep prion protein.

Authors:  Christoffer Lund; Christel M Olsen; Susan Skogtvedt; Heidi Tveit; Kristian Prydz; Michael A Tranulis
Journal:  J Biol Chem       Date:  2009-05-18       Impact factor: 5.157

Review 2.  Prion protein biosynthesis and its emerging role in neurodegeneration.

Authors:  Oishee Chakrabarti; Aarthi Ashok; Ramanujan S Hegde
Journal:  Trends Biochem Sci       Date:  2009-05-15       Impact factor: 13.807

3.  Molecular interaction of TPPP with PrP antagonized the CytoPrP-induced disruption of microtubule structures and cytotoxicity.

Authors:  Rui-Min Zhou; Yuan-Yuan Jing; Yan Guo; Chen Gao; Bao-Yun Zhang; Cao Chen; Qi Shi; Chan Tian; Zhao-Yun Wang; Han-Shi Gong; Jun Han; Bian-Li Xu; Xiao-Ping Dong
Journal:  PLoS One       Date:  2011-08-12       Impact factor: 3.240

4.  Cytosolic aggregates perturb the degradation of nontranslocated secretory and membrane proteins.

Authors:  Oishee Chakrabarti; Neena S Rane; Ramanujan S Hegde
Journal:  Mol Biol Cell       Date:  2011-03-16       Impact factor: 4.138

5.  Levels of the Mahogunin Ring Finger 1 E3 ubiquitin ligase do not influence prion disease.

Authors:  Derek Silvius; Rose Pitstick; Misol Ahn; Delisha Meishery; Abby Oehler; Gregory S Barsh; Stephen J DeArmond; George A Carlson; Teresa M Gunn
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

6.  Development of kinomic analyses to identify dysregulated signaling pathways in cells expressing cytoplasmic PrP.

Authors:  Rory H Shott; Cathy Appanah; Catherine Grenier; Guillaume Tremblay; Xavier Roucou; Luis M Schang
Journal:  Virol J       Date:  2014-10-03       Impact factor: 4.099

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.